{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:45Z","timestamp":1791406845866,"version":"4.3.3"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105218","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:19:32Z","timestamp":1771226372000},"page":"105218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Integrating STING activation with programmed death-ligand 1 inhibition: Novel approaches for cancer treatment"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0653-2724","authenticated-orcid":false,"given":"Hossein","family":"Khorramdelazad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhaneh","family":"Arfaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Yaraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Boroumand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Kheyri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Shirzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Kheiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105218_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1452212","article-title":"PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9\/10-CXCR3-IFN\u03b3 positive feedback loop","volume":"15","author":"Abdala-Saleh","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib2","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1038\/ncomms6166","article-title":"Inflammation-driven carcinogenesis is mediated through STING","volume":"5","author":"Ahn","year":"2014","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050880","article-title":"Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy","volume":"17","author":"Almawash","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105218_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1546717","article-title":"Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors","volume":"16","author":"Alsaafeen","year":"2025","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105218_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112695","article-title":"STING Agonists as Cancer Therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7689","key":"10.1016\/j.critrevonc.2026.105218_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib8","article-title":"Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy","volume":"11","author":"Bao","year":"2024","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105218_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084190","article-title":"Type I Interferon Production of Plasmacytoid Dendritic Cells under Control","volume":"22","author":"Bencze","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","article-title":"Interferon-stimulated neutrophils as a predictor of immunotherapy response","volume":"42","author":"Benguigui","year":"2024","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105218_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113182","article-title":"NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19","volume":"10","author":"Bergantini","year":"2021","journal-title":"Cells"},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105218_bib13","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105218_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1328651","article-title":"Targeting the immune microenvironment for ovarian cancer therapy","volume":"14","author":"Blanc-Durand","year":"2023","journal-title":"Front Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105218_bib15","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.7150\/ijbs.85236","article-title":"Activation of STING by SAMHD1 Deficiency Promotes PANoptosis and Enhances Efficacy of PD-L1 Blockade in Diffuse Large B-cell Lymphoma","volume":"19","author":"Cai","year":"2023","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105218_bib16","first-page":"S626","article-title":"1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors","volume":"34","author":"Calvo","year":"2023","journal-title":"Ann. Oncol."},{"issue":"6282","key":"10.1016\/j.critrevonc.2026.105218_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib18","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/acs.jmedchem.1c02197","article-title":"Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer","volume":"65","author":"Chang","year":"2022","journal-title":"J. Med Chem."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/jcmm.12294","article-title":"A novel TLR2-triggered signalling crosstalk synergistically intensifies TNF-mediated IL-6 induction","volume":"18","author":"Chang","year":"2014","journal-title":"J. Cell Mol. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-023-00551-z","article-title":"Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy","volume":"12","author":"Chen","year":"2024","journal-title":"Biomark. Res"},{"key":"10.1016\/j.critrevonc.2026.105218_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122259","article-title":"Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway","volume":"301","author":"Cheng","year":"2023","journal-title":"Biomaterials"},{"issue":"43","key":"10.1016\/j.critrevonc.2026.105218_bib22","doi-asserted-by":"crossref","first-page":"29439","DOI":"10.1021\/acsnano.3c12337","article-title":"Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy","volume":"18","author":"Cheng","year":"2024","journal-title":"ACS Nano"},{"issue":"47","key":"10.1016\/j.critrevonc.2026.105218_bib23","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112258118","article-title":"PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage","volume":"118","author":"Cheon","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6506","key":"10.1016\/j.critrevonc.2026.105218_bib24","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.abb4255","article-title":"Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic","volume":"369","author":"Chin","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib25","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1038\/s41467-024-54293-z","article-title":"Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy","volume":"15","author":"Choi","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105218_bib26","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.4049\/jimmunol.1300097","article-title":"Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid","volume":"190","author":"Conlon","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the Treatment of Cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interferon Cytokine Res"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib28","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105218_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108058","article-title":"STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status","volume":"199","author":"De Giglio","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105218_bib30","article-title":"Sudocetaxel Zendusortide (TH1902) triggers the cGAS\/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing","volume":"15","author":"Demeule","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib31","article-title":"The role of cGAS-STING pathway ubiquitination in innate immunity and multiple diseases","volume":"16","author":"Deng","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib32","article-title":"Harnessing single-cell and multi-omics insights: STING pathway-based predictive signature for immunotherapy response in lung adenocarcinoma","volume":"16","author":"Ding","year":"2025","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib33","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib34","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1038\/s41467-023-41164-2","article-title":"Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy","volume":"14","author":"Dou","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib35","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation","volume":"112","author":"Du","year":"2022","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1158\/0008-5472.CAN-23-1418","article-title":"Integration of Pan-Cancer Single-Cell and Spatial Transcriptomics Reveals Stromal Cell Features and Therapeutic Targets in Tumor Microenvironment","volume":"84","author":"Du","year":"2024","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105218_bib37","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.1021\/acs.jmedchem.3c00907","article-title":"Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates","volume":"66","author":"Duvall","year":"2023","journal-title":"J. Med Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib38","first-page":"713","article-title":"Lignin-assisted construction of sub-10\u00a0nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors","volume":"17","author":"Fan","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105218_bib39","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4881","article-title":"Reprogramming Cancer Cells to Antigen-presenting Cells","volume":"13","author":"Ferreira","year":"2023","journal-title":"Bio Protoc."},{"key":"10.1016\/j.critrevonc.2026.105218_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1334769","article-title":"Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists","volume":"15","author":"Filderman","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2326-6066.CIR-16-0284","article-title":"A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice","volume":"5","author":"Foote","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","article-title":"CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"Franken","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105218_bib44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jconrel.2023.10.017","article-title":"PAR2 deficiency tunes inflammatory microenvironment to magnify STING signalling for mitigating cancer metastasis via anionic CRISPR\/Cas9 nanoparticles","volume":"363","author":"Fu","year":"2023","journal-title":"J. Control Release"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib46","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","article-title":"Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy","volume":"122","author":"Garland","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.critrevonc.2026.105218_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102227","article-title":"Turning tumors from cold to inflamed to improve immunotherapy response","volume":"101","author":"Gerard","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","article-title":"STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer","volume":"119","author":"Ghaffari","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300028","article-title":"Targeting STING Activation by Antigen-Inspired MnO(2) Nanovaccines Optimizes Tumor Radiotherapy","volume":"12","author":"Gu","year":"2023","journal-title":"Adv. Health Mater."},{"key":"10.1016\/j.critrevonc.2026.105218_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/bs.ircmb.2018.07.001","article-title":"Macrophages: Their Untold Story in T Cell Activation and Function","volume":"342","author":"Guerriero","year":"2019","journal-title":"Int Rev. Cell Mol. Biol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101425","article-title":"Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation","volume":"43","author":"Guo","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.critrevonc.2026.105218_bib52","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9120","article-title":"Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)","author":"Hadfield","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib53","doi-asserted-by":"crossref","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/14796694.2024.2441107","article-title":"Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors","volume":"21","author":"Harrington","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib55","doi-asserted-by":"crossref","unstructured":"Harrington, K., Parkes, E., Weiss, J., Ingham, M., Cervantes, A., Calvo, E., Klinkhardt, U., Sikken, P., Schmohl, M., Garralda, E., 2021. Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors, CANCER RESEARCH. AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA \u2026.","DOI":"10.1158\/1538-7445.AM2021-CT217"},{"key":"10.1016\/j.critrevonc.2026.105218_bib56","first-page":"0","article-title":"Phase I study of MK\u20111454, a STING agonist, alone and in combination with pembrolizumab, in patients with advanced solid tumors or lymphoma, ESMO Congress","author":"Harrington K","year":"2018","journal-title":"Munich Ger. p. Abstr. LBA4"},{"key":"10.1016\/j.critrevonc.2026.105218_bib57","doi-asserted-by":"crossref","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105218_bib58","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","article-title":"Clinical implications of KEAP1-NFE2L2 mutations in NSCLC","volume":"16","author":"Hellyer","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","article-title":"The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy","volume":"25","author":"Hines","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105218_bib61","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib62","article-title":"Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: a comprehensive review of strategies and future perspectives","volume":"23","author":"Huang","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.critrevonc.2026.105218_bib63","first-page":"2024","article-title":"Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Immunol."},{"issue":"Pt A","key":"10.1016\/j.critrevonc.2026.105218_bib64","article-title":"Targeting STING for cancer immunotherapy: From mechanisms to translation","volume":"113","author":"Huang","year":"2022","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib65","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12967-025-06843-2","article-title":"The cGAS-STING pathway: a dual regulator of immune response in cancer and therapeutic implications","volume":"23","author":"Huang","year":"2025","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105218_bib66","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fchbi.2025.1549003","article-title":"Multifaceted roles of STING in tumors: from molecular mechanisms to therapeutic strategies","volume":"4","author":"Hussain","year":"2025","journal-title":"Front. Chem. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011572","article-title":"Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies","volume":"13","author":"Jacoby","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105218_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3162","article-title":"A phase Ia\/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors","author":"Janku","year":"2020","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105218_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216274","article-title":"Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models","volume":"24","author":"Jekle","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13578-023-01188-z","article-title":"The crucial regulatory role of type I interferon in inflammatory diseases","volume":"13","author":"Ji","year":"2023","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib71","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/pharmaceutics15020638","article-title":"Liposomal delivery of MIW815 (ADU-S100) for potentiated STING activation","volume":"15","author":"Ji","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105218_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00916-z","article-title":"cGAS-STING, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105218_bib74","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2147\/DDDT.S467835","article-title":"Development of Intratumoral Drug Delivery Based Strategies for Antitumor Therapy","volume":"18","author":"Jiang","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.critrevonc.2026.105218_bib75","article-title":"Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms","volume":"191","author":"Jianwei","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib76","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.4049\/jimmunol.2000026","article-title":"The Structural Basis of IRF-3 Activation upon Phosphorylation","volume":"205","author":"Jing","year":"2020","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib77","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17122001","article-title":"Blood-Based Biomarkers as Predictive and Prognostic Factors in Immunotherapy-Treated Patients with Solid Tumors-Currents and Perspectives","volume":"17","author":"Kaczmarek","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888147","article-title":"Post-Translational Modifications of STING: A Potential Therapeutic Target","volume":"13","author":"Kang","year":"2022","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105218_bib82","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1373\/clinchem.2017.286229","article-title":"Checkpoint Checkmate: Microbiota Modulation of Cancer Immunotherapy","volume":"64","author":"Keen","year":"2018","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib83","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846935","article-title":"Role of the cGAS\u2013STING pathway in cancer development and oncotherapeutic approaches","volume":"19","author":"Khoo","year":"2018","journal-title":"EMBO Rep."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105218_bib84","article-title":"Targeted STING Activation Using Modified Ultrasound-Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma","volume":"12","author":"Khorsandi","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib85","doi-asserted-by":"crossref","first-page":"840","DOI":"10.4049\/jimmunol.1301601","article-title":"DOK3 is required for IFN-\u03b2 production by enabling TRAF3\/TBK1 complex formation and IRF3 activation","volume":"193","author":"Kim","year":"2014","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib86","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1083673","article-title":"STINGing the Tumor's immune evasion mechanism","volume":"7","author":"Kim","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105218_bib87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jare.2022.05.006","article-title":"STING as an emerging therapeutic target for drug discovery: Perspectives from the global patent landscape","volume":"44","author":"Kong","year":"2023","journal-title":"J. Adv. Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib88","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255536","article-title":"STING agonism turns human T cells into interferon-producing cells but impedes their functionality","volume":"24","author":"Kuhl","year":"2023","journal-title":"EMBO Rep."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105218_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111769","article-title":"Cancer cell-derived type I interferons instruct tumor monocyte polarization","volume":"41","author":"Kwart","year":"2022","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib90","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS\u2013STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105218_bib91","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing Cancer Immunotherapies That Engage T Cells and NK Cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu Rev. Immunol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105218_bib92","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105218_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2020.06.004","article-title":"Balancing STING in antimicrobial defense and autoinflammation","volume":"55","author":"Landman","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105218_bib94","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41419-022-05217-6","article-title":"STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells","volume":"13","author":"Lee","year":"2022","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib95","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00262-022-03220-6","article-title":"Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer","volume":"71","author":"Lee","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105218_bib96","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance Mechanisms of Anti-PD1\/PDL1 Therapy in Solid Tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105218_bib97","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING promotes the growth of tumors characterized by low antigenicity via IDO activation","volume":"76","author":"Lemos","year":"2016","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001182","article-title":"Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity","volume":"8","author":"Lemos","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib99","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","article-title":"cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors","volume":"81","author":"Li","year":"2024","journal-title":"Cell Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10238-025-01838-1","article-title":"Unlocking the therapeutic potential of the STING signaling pathway in anti-tumor treatment","volume":"25","author":"Li","year":"2025","journal-title":"Clin. Exp. Med"},{"key":"10.1016\/j.critrevonc.2026.105218_bib101","article-title":"Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications","volume":"30","author":"Li","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-024-01576-z","article-title":"Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib103","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1039\/D0BM00870B","article-title":"The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma","volume":"9","author":"Li","year":"2021","journal-title":"Biomater. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib104","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nchembio.1661","article-title":"Hydrolysis of 2\u2032 3\u2032-cGAMP by ENPP1 and design of nonhydrolyzable analogs","volume":"10","author":"Li","year":"2014","journal-title":"Nat. Chem. Biol."},{"issue":"7931","key":"10.1016\/j.critrevonc.2026.105218_bib105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","article-title":"STING-induced regulatory B cells compromise NK function in cancer immunity","volume":"610","author":"Li","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib106","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS\u2013cGAMP\u2013STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111667","article-title":"Regulation of pattern recognition receptor signaling by palmitoylation","volume":"28","author":"Li","year":"2025","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib108","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.immuni.2013.10.019","article-title":"Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization","volume":"39","author":"Li","year":"2013","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib109","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.apsb.2024.02.006","article-title":"Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307580","article-title":"Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma","volume":"19","author":"Liang","year":"2024","journal-title":"Plos One"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105218_bib111","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and Stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib112","doi-asserted-by":"crossref","first-page":"91","DOI":"10.14218\/JCTH.2023.00197","article-title":"Update on the STING Signaling Pathway in Developing Nonalcoholic Fatty Liver Disease","volume":"12","author":"Liu","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib113","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/imm.12561","article-title":"The emerging roles of the STING adaptor protein in immunity and diseases","volume":"147","author":"Liu","year":"2016","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib114","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ymthe.2023.03.026","article-title":"Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity","volume":"31","author":"Liu","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105218_bib115","article-title":"Updated roles of cGAS-STING signaling in autoimmune diseases","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib116","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy","volume":"26","author":"Liu","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105218_bib117","article-title":"Interferon lambda in respiratory viral infection: immunomodulatory functions and antiviral effects in epithelium","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121871","article-title":"Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy","volume":"291","author":"Lu","year":"2022","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib119","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1021\/acscentsci.3c01122","article-title":"Orthogonal hydroxyl functionalization of cGAMP confers metabolic stability and enables antibody conjugation","volume":"9","author":"Lu","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105218_bib120","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-23-0118","article-title":"Phase I study of SYNB1891, an engineered E. coli nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies","volume":"29","author":"Luke","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105218_bib121","doi-asserted-by":"crossref","unstructured":"Lv, Q.-M., Wang, S.-Y., Lei, H.-M., Zhang, K.-R., Tang, Y.-B., Shen, Y., Lu, L.-M., Chen, H.-Z., Zhu, L., 2021. Cancer cell-autonomous cGAS-STING response confers drug resistance. bioRxiv, 2021.2010.2023.465546.","DOI":"10.1101\/2021.10.23.465546"},{"key":"10.1016\/j.critrevonc.2026.105218_bib122","series-title":"Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry. Volume 4","first-page":"1","article-title":"Discovery and chemical development of uvelostinag (MK-1454): A therapeutic cyclic dinucleotide agonist of the stimulator of interferon gene","author":"Maddess","year":"2022"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib123","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1038\/s41467-024-49932-4","article-title":"Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses","volume":"15","author":"Malli Cetinbas","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25074120","article-title":"The Golgi Apparatus: A Key Player in Innate Immunity","volume":"25","author":"M\u0103run\u0163elu","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105218_bib125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","article-title":"Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment","volume":"59","author":"Marzagalli","year":"2019","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.075","article-title":"Timely administration of drug combination improves chemoimmunotherapy of an immune-cold tumor","volume":"381","author":"Meng","year":"2025","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib127","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib128","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced\/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13040857","article-title":"The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances","volume":"13","author":"Morcillo-Mart\u00edn-Romo","year":"2025","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105218_bib130","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3390\/jcm9103323","article-title":"Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy","volume":"9","author":"Motedayen Aval","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.critrevonc.2026.105218_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115557","article-title":"Catalase-gold nanoaggregates manipulate the tumor microenvironment and enhance the effect of low-dose radiation therapy by reducing hypoxia","volume":"167","author":"Najafi","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105218_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113483","article-title":"Catalase application in cancer therapy: Simultaneous focusing on hypoxia attenuation and macrophage reprogramming","volume":"153","author":"Najafi","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"8003","key":"10.1016\/j.critrevonc.2026.105218_bib133","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-024-07134-4","article-title":"Universal recording of immune cell interactions in vivo","volume":"627","author":"Nakandakari-Higa","year":"2024","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105218_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005151","article-title":"T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer","volume":"10","author":"Ni","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41401-022-00953-z","article-title":"Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights","volume":"44","author":"Ni","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.critrevonc.2026.105218_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2024.104917","article-title":"The relationship between tumor immunity and the cGAS-STING pathway in breast cancer: An immunohistochemical study","volume":"139","author":"Nishida","year":"2024","journal-title":"Exp. Mol. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib137","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib138","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120540119","article-title":"Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1","volume":"119","author":"Oreskovic","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib139","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-022-00471-5","article-title":"STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer","volume":"8","author":"Pantelidou","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105218_bib140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1196829","article-title":"Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models","volume":"14","author":"Papaevangelou","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib141","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105218_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.830208","article-title":"Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies","volume":"10","author":"Park","year":"2022","journal-title":"Front Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib143","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer","volume":"109","author":"Parkes","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105218_bib144","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/0008-5472.CAN-24-1022","article-title":"STING Agonist VB-85247 Induces Durable Antitumor Immune Responses by Intravesical Administration in a Non-Muscle-Invasive Bladder Cancer","volume":"85","author":"Prabagar","year":"2025","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105218_bib145","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009803","article-title":"Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses","volume":"12","author":"Pulliam","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"42","key":"10.1016\/j.critrevonc.2026.105218_bib146","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado6342","article-title":"Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenance","volume":"10","author":"Pundavela","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105218_bib147","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1488345","article-title":"Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy","volume":"15","author":"Qi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib148","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.2147\/IJN.S515893","article-title":"Nanoparticle-Based Strategies to Enhance the Efficacy of STING Activators in Cancer Immunotherapy","volume":"20","author":"Qiao","year":"2025","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.critrevonc.2026.105218_bib149","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1158\/1538-7445.AM2025-6983","article-title":"Abstract 6983: Innovative oral STING agonists for cancer therapy","volume":"85","author":"Qin","year":"2025","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102530","article-title":"Conjugated STING agonists","volume":"36","author":"Qu","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105218_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118014","article-title":"Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota","volume":"186","author":"Rahimi","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105218_bib152","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","article-title":"Present Yourself! By MHC Class I and MHC Class II Molecules","volume":"37","author":"Rock","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.695056","article-title":"STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity","volume":"12","author":"Rossi","year":"2021","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105218_bib154","article-title":"The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability","volume":"4","author":"Roy","year":"2023","journal-title":"Cell Rep. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105218_bib155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005324","article-title":"Characterization of a novel human-specific STING agonist that elicits antiviral activity against emerging alphaviruses","volume":"11","author":"Sali","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.critrevonc.2026.105218_bib156","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","article-title":"Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response","volume":"4","author":"Schiavoni","year":"2013","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib157","article-title":"Nanoparticles-Mediated CRISPR-Cas9 systems for CAR T-cell immunotherapy as smart cancer biotherapeutics","author":"Seyyed Mojtaba","year":"2025","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.critrevonc.2026.105218_bib158","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.2147\/IJN.S462213","article-title":"Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth","volume":"19","author":"Shaji","year":"2024","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.critrevonc.2026.105218_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114627","article-title":"Structure\u2013Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists","volume":"241","author":"Shen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS\u2013STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib161","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","article-title":"Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective","volume":"25","author":"Sherafat","year":"2025","journal-title":"Clin. Exp. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib162","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib163","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell"},{"issue":"7559","key":"10.1016\/j.critrevonc.2026.105218_bib164","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105218_bib165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jconrel.2023.03.047","article-title":"Unlocking the promise of systemic STING agonist for cancer immunotherapy","volume":"357","author":"Sun","year":"2023","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib166","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-23-0700","article-title":"TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity","volume":"14","author":"Tani","year":"2024","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105218_bib167","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00262-022-03193-6","article-title":"CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy","volume":"71","author":"Tian","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105218_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.996663","article-title":"Cancer immunotherapy strategies that target the cGAS-STING pathway","volume":"13","author":"Tian","year":"2022","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib169","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.211991","article-title":"Targeting the PD-1\/PD-L1 axis for cancer treatment: a review on nanotechnology","volume":"9","author":"Tran","year":"2022","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.critrevonc.2026.105218_bib170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-pathmechdis-012418-013058","article-title":"Monocytes in the Tumor Microenvironment","volume":"16","author":"Ugel","year":"2021","journal-title":"Annu Rev. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib171","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1038\/s41467-024-47692-9","article-title":"The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion","volume":"15","author":"Uslu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105218_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2025.04.008","article-title":"Tumor-draining lymph nodes \u2013 friend or foe during immune checkpoint therapy?","author":"von Renesse","year":"2025","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib173","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jcmgh.2021.01.018","article-title":"STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer","volume":"12","author":"Vonderhaar","year":"2021","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib174","article-title":"Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib175","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib176","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.apsb.2023.12.010","article-title":"Small-molecule agents for cancer immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105218_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2024.103105","article-title":"Delivery of STING agonists for cancer immunotherapy","volume":"87","author":"Wang","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib178","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105218_bib179","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.343","article-title":"Hot and cold tumors: Immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105218_bib180","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.21037\/atm-22-6049","article-title":"Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review","volume":"10","author":"Wang","year":"2022","journal-title":"Ann. Transl. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib181","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-025-02380-0","article-title":"Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib182","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","article-title":"CAR-T therapy dilemma and innovative design strategies for next generation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105218_bib183","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Emerging cGAS-STING Agonist-Based Nanotherapeutics: Mechanistic Insights and Applications in Cancer Combination Therapy","author":"Wang","year":"2025","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib184","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000282","article-title":"Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma","volume":"8","author":"Wang-Bishop","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib185","doi-asserted-by":"crossref","DOI":"10.3390\/nu13030886","article-title":"The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies","volume":"13","author":"Wiertsema","year":"2021","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib186","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib187","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib188","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1084\/jem.20182192","article-title":"STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death","volume":"216","author":"Wu","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105218_bib189","article-title":"Advances in nanomaterials for enhancing cGAS-STING pathway mediated anti-tumor treatment","volume":"34","author":"Wu","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"49","key":"10.1016\/j.critrevonc.2026.105218_bib190","article-title":"Tumor-targeted delivery of a STING agonist improves cancer immunotherapy","volume":"119","author":"Wu","year":"2022","journal-title":"Proc. Natl. Acad. Sci.\u00a0USA"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib191","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molcel.2013.07.004","article-title":"The cGAS-STING Pathway for DNA Sensing","volume":"51","author":"Xiao","year":"2013","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib192","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12943-024-02166-w","article-title":"Cellular mechanisms of combining innate immunity activation with PD-1\/PD-L1 blockade in treatment of colorectal cancer","volume":"23","author":"Xie","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib193","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3892\/or.2023.8618","article-title":"Advances in the role of gut microbiota in the regulation of the tumor microenvironment (Review)","volume":"50","author":"Xinyuan","year":"2023","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105218_bib194","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.critrevonc.2026.105218_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1482738","article-title":"Targeting STING signaling for the optimal cancer immunotherapy","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib196","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5483\/BMBRep.2021.54.1.241","article-title":"Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity","volume":"54","author":"Yadollahi","year":"2021","journal-title":"BMB Rep."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105218_bib197","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1172\/JCI125413","article-title":"STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade","volume":"129","author":"Yang","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib198","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105218_bib199","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/15384101.2022.2029996","article-title":"STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-\u03b2 signalling pathway","volume":"21","author":"Yin","year":"2022","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105218_bib200","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00432-021-03879-x","article-title":"Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer","volume":"148","author":"Yu","year":"2022","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib201","doi-asserted-by":"crossref","DOI":"10.1042\/EBC20253006","article-title":"The cGAS-STING pathway in cancer immunity: dual roles, therapeutic strategies, and clinical challenges","author":"Yue","year":"2025","journal-title":"Essays Biochem."},{"issue":"02","key":"10.1016\/j.critrevonc.2026.105218_bib202","doi-asserted-by":"crossref","DOI":"10.1042\/EBC20253006","article-title":"The cGAS-STING pathway in cancer immunity: dual roles, therapeutic strategies, and clinical challenges","volume":"69","author":"Yue","year":"2025","journal-title":"Essays Biochem."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105218_bib203","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3892\/ijo.2024.5673","article-title":"Myeloid\u2011derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)","volume":"65","author":"Zeng","year":"2024","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib205","article-title":"Exosomes as smart drug delivery vehicles for cancer immunotherapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib206","first-page":"45","article-title":"Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies","volume":"21","author":"Zhang","year":"2024","journal-title":"Cancer Biol. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib207","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","article-title":"STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib208","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40364-025-00750-w","article-title":"Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark. Res"},{"key":"10.1016\/j.critrevonc.2026.105218_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217410","article-title":"STING in cancer immunoediting: Modeling tumor-immune dynamics throughout cancer development","volume":"612","author":"Zhang","year":"2025","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/imm.13592","article-title":"The paradoxical role of radiation-induced cGAS\u2013STING signalling network in tumour immunity","volume":"168","author":"Zhang","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105218_bib211","article-title":"Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105218_bib212","first-page":"1256","article-title":"Expression of STING and PD-L1 in colorectal cancer and their correlation with clinical prognosis","volume":"11","author":"Zhong","year":"2018","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib213","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1438364","article-title":"Investigating the impact of STING pathway activation on breast cancer treatment outcomes: development and validation of a prognostic model","volume":"15","author":"Zhong","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101007","article-title":"Nanodelivery of STING agonists against cancer and infectious diseases","volume":"83","author":"Zhou","year":"2022","journal-title":"Mol. Asp. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105218_bib215","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202100133","article-title":"Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy","volume":"21","author":"Zhou","year":"2021","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.critrevonc.2026.105218_bib216","article-title":"Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1\/PD-L1 Blockade Therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105218_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104933","article-title":"A synthetic STING agonist inhibits the replication of human parainfluenza virus 3 and rhinovirus 16 through distinct mechanisms","volume":"183","author":"Zhu","year":"2020","journal-title":"Antivir. Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib218","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","article-title":"Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105218_bib219","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","article-title":"Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:47:04Z","timestamp":1775908024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":219,"alternative-id":["S1040842826001058"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105218","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating STING activation with programmed death-ligand 1 inhibition: Novel approaches for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105218"}}